Tilray Brands consolidates its global medical offering into Tilray Medical, a comprehensive portfolio of brands and products

The new division brings together the medical activities inherited from Tilray and Aphria; Includes extended offers in Canada

TORONTO, Feb. 08 Feb. 20, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis and consumer packaged goods that inspires and empowering the global community to live their best lives, today announced the launch of Tilray Medical, a global medical platform that unifies the company’s medical cannabis brands under one strategy, mission and vision.

Denise Faltischek, Head of International Strategy and Chief Strategy Officer, said, “Tilray is the global leader in advancing cannabinoid medicine, with a focus on providing research-backed medical cannabis products. to doctors, pharmacies and patients. By uniting the global medical divisions of Tilray and Aphria under a cohesive strategy and mission, Tilray Medical emerges as the premier global provider of a portfolio of high-quality, effective medical cannabis brands and products for patients in need around the world. »

As part of Tilray Medical’s consolidation plan, patients in Canada will have the broadest access to our medical cannabis brands and product choices globally, including Tilray, Aphria, Broken Coast and Symbios. Subject to local regulatory approvals, Tilray Medical’s global portfolio of medical cannabis products includes high-quality, GMP-certified flowers, oils, vapes, edibles and topicals. Going forward, Tilray Medical will continue to expand its offering to patients around the world.

About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering the dignity of patients in need through safe and trusted access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast and Symbios. Tilray went from being one of the first companies to become a licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and then in Germany. Today, Tilray Medical is one of the largest branded suppliers of medical cannabis to patients, doctors, hospitals, pharmacies, researchers and governments, in 20 countries and on five continents.

For more information about Tilray Medical, visit Tilray Medical Canada, Tilray Medical Australia, Tilray Medical Australia-New Zealand, Tilray Medical Europe

About Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America, changing people’s lives for the better – one person at a time. Tilray Brands fulfills this mission by inspiring and empowering the global community to live their best life and by providing access to products that meet the needs of their mind, body and soul while invoking The well-being. Patients and consumers trust Tilray Brands to deliver a cultured experience of health and well-being through differentiated, high-quality brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray’s unparalleled production platform supports more than 20 brands in over 20 countries, including complete cannabis offerings, hemp edibles and craft drinks.

For more information on how we are opening up a world of wellness, visit www.Tilray.com.

Forward-looking statements

Certain statements contained in this communication that are not historical facts constitute forward-looking information or forward-looking statements (collectively, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended. , and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “anticipate”, “future”, “should”, “could”, “allow”, “potential”, “envisage”, “believe”, “anticipate”, “estimate, “plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative form of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, objectives, projections or assumptions have been used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, prospects, analyzes or current expectations regarding, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients around the world, including through Tilray Medical. Many factors could cause actual results, performance or achievements to differ materially from any forward-looking statements, and other risks and uncertainties currently unknown to the Company or that the Company deems immaterial could also cause actual results or events will differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see Tilray’s most recently filed annual information sheet and Tilray’s annual report on Form 10-K (and other periodic reports filed with the SEC) of Tilray written with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication, and the Company undertakes no obligation to publicly update these forward-looking statements to reflect new information, subsequent events or otherwise, except as required by securities laws. applicable securities so require.

contacts:

Tilray Brands:
Berrin Noorata
news@tilray.com

Investors
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com

Source link

About Alex S. Crone

Check Also

Experts Highlight Industry Challenges, Marketing & Advertising News, ET BrandEquity

Representative image (iStock) The top 300 widely used drug brands will have Quick Response (QR) …